The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry.

"Conflict of Interest The corresponding author confirms on behalf of all authors that there have been no involvements that might raise the question of bias in the work reported or in the conclusions, implications or opinions stated. M.A. receives research support from the Dickler Family Fund, New York Community Trust and the Helmsley Charitable Trust Fund for SECURE-IBD. X.Z. reports no conflict of interest. E.J.B. is supported by an Institutional Training Grant from the National Institutes of Health [T32DK007634]. R.C.U. has served as a consultant and/or advisory board member for Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer and Takeda. He has received research support from AbbVie, Boehringer Ingelheim and Pfizer. He is supported by a Career Development Award from the National Institutes of Health [K23KD111995-01A1]. M.D.K. has consulted for Abbvie, Janssen, Pfizer and Takeda, is a shareholder in Johnson & Johnson, and has received research support from Pfizer, Takeda, Janssen, Abbvie, Lilly, Genentech, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion and Arenapharm. J.F.C. reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Landos, Ipsen, Medimmune, Merck, Novartis, Pfizer, Shire, Takeda, Tigenix and Viela bio; and holds stock options in Intestinal Biotech Development and Genfit."

"Funding This work was funded by the Helmsley Charitable Trust [2003–04445], National Center for Advancing Translational Sciences [UL1TR002489], a T32DK007634 [E.J.B.] and a K23KD111995-01A1 [R.C.U.]. Additional funding was provided by Pfizer, Takeda, Janssen, Abbvie, Lilly, Genentech, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion and Arenapharm."